Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional
Official Title: An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids.
Brief Summary:
Lazanda is a prescription nasal spray medicine that contains the medicine fentanyl. It is used to manage breakthrough pain in adults with cancer who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Lazanda is started only after taking other opioid pain medicines and the patient's body has become used to them (opioid tolerant).
The purpose of this study is to assess the ability of Lazanda to control pain during an episode of breakthrough pain in cancer patients.